Where the evidence actually stands for psychedelic-assisted therapy in opioid, alcohol, and nicotine use disorders — with substance-specific deep dives.
Psychedelic therapy for addiction is the area where the field’s results have been most striking. In tightly controlled trials, a single dose of psilocybin has produced heavy-drinking reductions that standard-of-care medications rarely match. A single ibogaine session has ended opioid withdrawal in observational cohorts. Ketamine has been used in structured psychotherapy for alcohol dependence for decades. None of this means the case is closed.
No psychedelic is FDA-approved for any addiction indication in 2026. The strongest results come from small trials, and the largest confirmatory studies are still enrolling. This guide summarizes what is signal, what is confirmed, and where each substance actually fits. Every claim below links to a deeper guide with the specific studies, authors, and years.
Psychedelic therapy for addiction is a limited course of high-dose psychedelic sessions delivered inside a structured psychotherapy protocol, not a stand-alone drug prescription. The typical model is one to three dosing sessions embedded in eight to twelve psychotherapy sessions, drawn from motivational interviewing, cognitive-behavioral therapy, or acceptance-based approaches.
The framing matters. “Psychedelic-assisted therapy” is the term researchers use specifically to distance the field from recreational or ceremonial use. Recreational use of psychedelics does not produce the outcomes seen in trials. The results appear to correlate strongly with the quality of the surrounding psychotherapy protocol, not just the drug — a point that “top-line result” press coverage rarely surfaces.
This has an unusual regulatory consequence. Any FDA approval in addiction would likely require both the psychedelic and the specific psychotherapy protocol to be approved together. That is uncommon for the FDA, and it is one of several reasons an approval remains years away even for the strongest signals.
Different psychedelics have accumulated evidence in different indications. The table below is the shortest honest summary of the 2026 landscape.
| Indication | Strongest-evidence psychedelic | Study anchor | Access today |
|---|---|---|---|
| Opioid use disorder | Ibogaine | Cherian et al., Nature Medicine 2024 (MISTIC); Ona et al. 2023 systematic review | International clinics; Texas IMPACT trials enrolling |
| Alcohol use disorder | Psilocybin | Bogenschutz et al., JAMA Psychiatry 2022 RCT | Clinical trials; multi-site confirmatory RCT enrolling |
| Nicotine dependence | Psilocybin | Johnson et al. 2014 Johns Hopkins pilot | NIDA-funded confirmatory RCT enrolling |
| Stimulant use disorder | Ibogaine (observational only) | Mash et al. 2018 observational | International clinics; no confirmatory RCTs |
Opioid use disorder. Ibogaine dominates. It appears to interrupt withdrawal and blunt craving in a way no other psychedelic does. See ibogaine for opioid addiction for the full trial map.
Alcohol use disorder. Psilocybin has the strongest controlled trial in the field. Ibogaine and ketamine both have observational and older RCT support. See psilocybin for alcohol use disorder and ibogaine for alcoholism.
Nicotine dependence. Psilocybin is the only psychedelic with a serious research program in smoking cessation. See psilocybin for smoking cessation.
Stimulant use disorder. The evidence is thinnest here. Ibogaine has observational support for cocaine and methamphetamine dependence, but no confirmatory RCTs exist.
Ibogaine is the psychedelic with the sharpest addiction signal. A single 10–20 mg/kg oral dose can end opioid withdrawal within hours and blunt craving for weeks. Observational cohorts from Mexican clinics consistently report abstinence rates well above standard medication-assisted treatment benchmarks, and the Stanford MISTIC trial (Cherian et al., Nature Medicine 2024) documented the magnesium-ibogaine safety protocol that lets modern trials move forward.
Texas appropriated $50 million in 2025 via Senate Bill 2308, and the IMPACT consortium led by UTHealth Houston and UTMB Health will pursue FDA-authorized trials in opioid use disorder, traumatic brain injury, and PTSD. See the ibogaine guide for the pharmacology and the best ibogaine treatment centers roundup for current international access.
Psilocybin for alcohol use disorder has the cleanest randomized controlled evidence in the whole field of psychedelic addiction research. Bogenschutz et al., JAMA Psychiatry 2022, randomized 93 adults with alcohol use disorder to two psilocybin sessions or two diphenhydramine sessions, both embedded in the same manualized psychotherapy. The psilocybin arm averaged 9.7% heavy drinking days over 32 weeks vs. 23.6% on placebo — a 13.9-percentage-point difference (p=0.01), roughly a 59% relative reduction versus placebo (and about 83% down from each arm’s own baseline).
A multi-site confirmatory RCT is enrolling. The Bogenschutz protocol is also the reference example of how much the surrounding psychotherapy carries the result. Both arms received the same structured therapy; the psilocybin arm did dramatically better. See psilocybin for alcohol use disorder for the full protocol and outcomes.
Psilocybin for smoking cessation has the highest headline number in the entire addiction literature: Johnson et al. 2014 at Johns Hopkins reported 80% biologically verified abstinence at six months in a 15-person open-label pilot. That is roughly triple the best standard-of-care benchmarks for varenicline or nicotine replacement.
Pilot results at this magnitude usually shrink when confirmatory trials run. A NIDA-funded multi-site randomized trial comparing psilocybin to nicotine replacement is currently enrolling and will decide whether the pilot signal holds. See psilocybin for smoking cessation for the exact study design and current trial status.
Ketamine is the most legally accessible psychedelic in US addiction care, but the evidence is adjunctive, not curative. Evgeny Krupitsky’s ketamine-psychotherapy work for alcohol dependence in the 1990s and 2000s established the model: sub-anesthetic ketamine sessions embedded in psychotherapy, producing durable reductions in drinking in the treated arm. Awakn Life Sciences ran the KARE trial (ketamine-assisted therapy for alcohol use disorder) building on the same framework.
Ketamine is Schedule III in the US and can be prescribed off-label, which is why ketamine-assisted psychotherapy is the only form of psychedelic therapy for addiction legally available in the US today. It is best used as one component of a broader recovery plan, not a stand-alone treatment. See the ketamine guide and ibogaine vs. ketamine for how the two compare in addiction settings.
Ayahuasca appears repeatedly in first-person recovery accounts, including public accounts from figures like former NFL receiver Kenny Stills, and in observational research on long-term ceremonial users. Fabrègas et al. and other Brazilian groups have reported lower rates of substance dependence among long-term ayahuasca users than in matched controls.
What is missing is randomized controlled evidence. No RCT has tested ayahuasca in a formal addiction indication. The signal is real enough to note; the confirmation is not there. See the ayahuasca guide for what is documented.
The FDA-approved standard of care for addiction includes medication-assisted treatment (naltrexone, methadone, and buprenorphine for opioid use disorder; naltrexone and acamprosate for alcohol use disorder; varenicline and nicotine replacement for nicotine dependence) plus behavioral therapy. This is where most patients should start — not because psychedelics do not work, but because the standard-of-care evidence base is deeper, coverage is broader, and access is easier.
| Psychedelic-assisted therapy | Medication-assisted treatment (MAT) | Behavioral therapy alone | |
|---|---|---|---|
| Evidence base by indication | Strongest: psilocybin for AUD; ibogaine (observational) for OUD; psilocybin pilot for smoking | Strongest: methadone/buprenorphine for OUD; naltrexone/acamprosate for AUD; varenicline for smoking | Moderate; reliably improves outcomes when combined with medication |
| Format | 1–3 high-dose sessions inside 8–12 therapy sessions | Daily or long-acting medication plus periodic clinical visits | Weekly therapy for months |
| Duration | Weeks to a few months | Months to years; often long-term | Months |
| Cost | $6,000–$18,000 for ibogaine internationally; ketamine ~$300–$800/session; trial participation free | Often covered; low out-of-pocket cost | Often covered |
| Insurance coverage | Rarely covered outside ketamine for depression | Broadly covered | Broadly covered |
| Legal access (US) | Ketamine only; other substances via clinical trial or abroad | Widely available by prescription | Widely available |
| Cardiac / medical risk | Ibogaine: significant cardiac risk; psilocybin/ketamine: modest, screenable | Generally well-characterized; varies by drug | Minimal |
When psychedelic therapy might fit. When standard care has been tried and has not worked, or when the goal is a short structured course rather than long-term medication, or when the specific indication has strong psychedelic evidence (alcohol, smoking, opioids for ibogaine). It is not a replacement for medication-assisted treatment in a patient already stable on it. And it is not an escape hatch from the hard part of recovery — the therapy is doing at least as much work as the drug.
There are three legal lanes in 2026, and one common misunderstanding to avoid.
What is not a legal access lane. The Oregon and Colorado psilocybin service center programs are adult-use models, not medical treatment. They are not authorized to treat addiction as a medical condition, do not require or provide diagnostic assessment, and are not staffed with licensed addiction clinicians. That is a real distinction that gets blurred in media coverage.
Integration therapy is the structured psychotherapy that surrounds the dosing sessions and turns an experience into durable behavior change. In the Bogenschutz alcohol trial and the Johnson smoking pilot, the psychedelic session is one element of an 8–12 session protocol; skipping the psychotherapy is skipping most of the treatment.
This is also why unstructured recreational psychedelic use is not a substitute for psychedelic therapy for addiction. The dose is the smaller half of the intervention. See the integration therapy guide for how the protocols are structured.
Psychedelic therapy is not appropriate for everyone in recovery, and screening exists for real reasons. Absolute or near-absolute contraindications include:
See the psychedelic medication safety guide for the full contraindication list and specific medication interactions.
Psychedelic therapy for addiction is where the field has produced its most striking results and its most credible near-term clinical programs. But no psychedelic is FDA-approved for any addiction indication in 2026, the largest confirmatory trials are still enrolling, and the therapy is doing at least as much work as the drug. The right first step depends on the specific substance problem, the medical history, and whether standard-of-care medications have already been tried.
Not sure where to start? Our which psychedelic quiz maps your situation to the option with the strongest evidence for your goal. The clinical trial finder shows what is enrolling now. If you or someone you know is in active crisis, please see the crisis resources page first.
Ibogaine has the strongest single-indication signal in the field — specifically for opioid use disorder. Observational data from Mexican and Costa Rican clinics reports high rates of interruption of opioid use after a single dose, and Stanford's 2024 MISTIC trial in special-operations veterans reported no serious cardiac events under the magnesium-ibogaine protocol. Psilocybin has the strongest controlled evidence for alcohol use disorder, from Bogenschutz et al.'s 2022 JAMA Psychiatry trial.
No. As of 2026 the FDA has not approved any psychedelic-assisted therapy for any addiction indication. Ketamine (Schedule III) is legally prescribed off-label for depression and can be adjunctive in recovery care; Spravato (esketamine) is FDA-approved for treatment-resistant depression, not addiction. Ibogaine and psilocybin remain Schedule I federally.
No responsible clinician or researcher describes it as a cure. The framing in the peer-reviewed literature is that a psychedelic session can create a window of reduced craving and increased motivation for change, which integration therapy and standard recovery supports then use to build durable behavior change. Relapse remains common, particularly without integration support.
Ketamine therapy is legally available from US-licensed clinicians and can be used adjunctively in recovery care. Psilocybin is legal for adults in Oregon (Measure 109) and Colorado (Prop 122) service centers, though those programs are not addiction-specific. Ibogaine requires either enrollment in an FDA-IND trial (Texas IMPACT, DemeRx) or travel to a clinic in Mexico, Costa Rica, or Portugal.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.